Company profile
TriSalus Life Sciences, Inc.
NASDAQ:TLSIMedical Specialities
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| IPILIMUMAB | phase1_2 | — | 128 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04935229 | phase1 | terminated | 2021-08-02 | 2024-07-17 | TriSalus Life Sciences, Inc. | Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma |
| NCT05220722 | phase1_2 | terminated | 2022-03-02 | 2024-07-31 | TriSalus Life Sciences, Inc. | Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors |
| NCT05607953 | phase1 | active_not_recruiting | 2023-03-01 | 2027-09-01 | TriSalus Life Sciences, Inc. | Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma |
FDA applications (0)
No records yet.